Drug news
NICE now recommends Xolair (Novartis) for Allergic Asthma
NICE,the National Institute for Health and Clinical Excellence said it now recommends Xolair (omalizumab) from Novartis as an option for treating severe, persistent Allergic Asthma in adults, adolescents and children, in a complete change from its earlier intention to exclude it from the NHS.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.